Privia Health

PRVA

Market cap $3B

Privia Health Group, Inc. ( PRVA ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Robert Borchert - Senior Vice President of Investor Relations & Corporate Communications Parth Mehrotra - CEO & Director David Mountcastle - Executive VP, CFO & Principal Accounting Officer Conference Call Participants Marco Criscuolo - Nephron Research LLC Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Benjamin Mayo - Leerink Partners LLC, Research Division Matthew Gillmor - KeyBanc Capital Markets Inc., Research Division Thomas Walsh - Barclays Bank PLC, Research Division Matthew Shea - Needham & Company, LLC, Research Division Jailendra Singh - Truist Securities, Inc., Research Division Jeffrey Garro - Stephens Inc., Research Division Ryan Langston - TD Cowen, Research Division Albert Rice - UBS Investment Bank, Research Division Constantine Davides - Citizens JMP Securities, LLC, Research Division Derek Gross - Piper Sandler & Co., Research Division Daniel Grosslight - Citigroup Inc., Research Division Jack Slevin - Jefferies LLC, Research Division Jenny Shen - BTIG, LLC, Research Division Ryan Daniels - William Blair & Company L.L.C., Research Division Presentation Operator Hello, and welcome to the Privia Health Third Quarter 2025 Results Conference Call.

The headline numbers for Privia Health (PRVA) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Privia Health (PRVA) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.03 per share a year ago.

Privia Health Reports Very Strong Q3 and YTD Results Across the Business; FY'25 Guidance Raised Above High End for All Key Operating and Financial Metrics

Privia Health Group offers high-growth potential with a recurring revenue model and strong relationships, making it attractive amid the healthcare sector underperformance. PRVA's recent acquisition of Evolent Health's ACO adds over 120,000 users, boosting revenue streams and raising expectations for the next earnings report. Despite a high forward P/E and a DCF model suggesting downside, technical patterns and sector comps support a potential breakout above $26, targeting $28–$36.

ARLINGTON, Va., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its third-quarter and nine-month periods ended September 30, 2025 before market open on Thursday, November 6, 2025.

Privia Health Group, Inc. PRVA on Tuesday agreed to acquire an Accountable Care Organization (ACO) business from Evolent Health, Inc. EVH.

ARLINGTON, Va., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced that it signed a definitive agreement to acquire an Accountable Care Organization (ACO) business from Evolent Health, Inc. (NYSE: EVH).

Transaction enhances focus on specialty condition management and accelerates Evolent's deleveraging path. Proceeds from the transaction to be used to prepay senior term debt; Immediately accretive to Evolent's free cash flow by more than $7 million per year.

– Mid-Atlantic ACO Realized Highest Savings Rate of All ACOs with 40,000+ Attributed Lives – Company Increases Adjusted EBITDA Guidance for Full-Year 2025 ARLINGTON, Va., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that its Accountable Care Organizations (ACOs) achieved shared savings of $233.1 million through the Medicare Shared Savings Program (MSSP) for the 2024 performance year, a 32% increase from 2023.